News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Start mfn-cus-pledox

Press releases

July 9, 2020

Positive pre-clinical results with PledOx published in Antioxidants

Regulatory

March 1, 2020

PledPharma places dosing of patients in the POLAR program on hold

Regulatory

January 23, 2020

PledPharma provides update on the clinical POLAR program, clinical hold in the US

December 16, 2019

Global phase III study POLAR-A fully recruited

December 10, 2019

PLEDPHARMA’S ASIAN PARTNER SOLASIA ENTERS AGREEMENT WITH JAPANESE MARUHO FOR COMMERCIALIZATION OF PLEDOX®

Regulatory

October 9, 2019

PledPharma and Solasia enter a second license agreement for the development and commercialisation of PledOx® in Asia, targeting neuropathy caused by taxanes and any other chemotherapy

May 31, 2019

PledPharma presents PledOx®’s global phase III program at ASCO

Regulatory

February 21, 2019

Year-end Report January-December 2018

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com